Study of GS-0151 in Participants With Rheumatoid Arthritis

PHASE1RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

May 14, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Rheumatoid Arthritis
Interventions
DRUG

GS-0151

Administered for 12 weeks

DRUG

Placebo

Administered for 12 weeks

Trial Locations (17)

16635

RECRUITING

Altoona Center for Clinical Research, Duncansville

23456

RECRUITING

Tidewater Clinical Research, LLC/ Virginia Rheumatology Clinic, Virginia Beach

33765

RECRUITING

Clinical Research of West Florida, Inc, Clearwater

36207

RECRUITING

Pinnacle Research Group, LLC, Anniston

60160

RECRUITING

DM Clinical Research, Melrose Park

60640

RECRUITING

Great Lakes Clinical Trials dba Flourish Research Chicago, Chicago

70605

RECRUITING

Accurate Clinical Research, Inc, Lake Charles

73112

RECRUITING

Lynn Health Science Institute, Oklahoma City

77089

RECRUITING

Accurate Clinical Research, Inc, Houston

77521

RECRUITING

Accurate Clinical Management, LLC, Baytown

78229

RECRUITING

Clinical Trials of Texas LLC, dba Flourish Research, San Antonio

90602

RECRUITING

Medvin Clinical Research, Whittier

91042

RECRUITING

Medvin Clinical Research, Tujunga

92037

RECRUITING

University of California, San Diego, La Jolla

94304

RECRUITING

Stanford University School of Medicine, Palo Alto

0112

RECRUITING

ARENSIA Exploratory Medicine, LLC, Tbilisi

MD-2025

RECRUITING

"Republican Clinical Hospital Timofei Mosneaga, Arensia EM", Chisinau

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY